Selective sensitivity of KRASG13C NSCLC to chemotherapy. A, Top 25 compounds demonstrating the highest sensitivity to KRASG13C-driven NSCLC cell lines compared with cell lines with other KRAS-mutant genotypes. Each dot represents a cell line and is the mean of two repeats. The dashed line indicates the midway point between the most resistant and the most sensitive cell line for every compound, with cell lines to the left of the dashed line deemed drug-sensitive and cell lines to the right deemed drug-resistant. Each cell line is considered a genotype-specific biological replicate: KRASG12C (blue), n = 4 cell lines; KRASG12D (red), n = 3 cell lines; KRASG13C (green), n = 2 cell lines; and KRASG13D (purple), n = 4 cell lines. The dot represents the mean of the technical duplicate. Black arrows indicate compounds of interest. B, 2D (left) and 3D (right) viability of advanced cancer cell lines expressing either KRASG12C (H358, H23, HCC1171, H2030, H1792, and HOP62), KRASG12D (SKLU-1, A427, and HCC461), KRASG13C (H1734, H1355, HCC4087, and MOR), or KRASG13D (H647, H1944, HCC515, and HCC1974) exposed to 1 μmol/L docetaxel, 1 μmol/L paclitaxel, 1 μmol/L vincristine, 1 μmol/L epirubicin, 1 μmol/L gemcitabine, and 100 μmol/L carboplatin. Viability was measured by CellTiter-Glo (3D) 72 hours later. Data are expressed as a percentage of DMSO control. n = 3 per cell line with the mean of three biological repeats shown as a dot. Error bars represent mean ± SEM of all cell lines within each condition (KRASG12C + KRASG12D + KRASG13D vs. KRASG13C). Two KRASG12C lines (H2030 and HCC1171) were excluded from vincristine response in 3D analysis due to a viability increase of more than 180% relative to DMSO control. C, PFS between patients with KRASG13C and those with KRASG12C, KRASG12D, KRASG12V, or KRASG13D NSCLC receiving first-line chemotherapy. Data are taken from the Francophone de Cancérologie Thoracique dataset (51). D, Dose-response analysis of isogenic MLE-12 cells previously treated with DOX for 24 hours to induce KRAS variant expression in 0.5% serum, followed by a 72-hour treatment with a concentration range of indicated chemotherapeutics. Cells were plated in ULA conditions. Viability was analyzed by CellTiter-Glo 3D. Data are expressed as a percentage of DMSO control. n = 3 biological repeats per isogenic cell line; mean ± SEM. IC values were calculated for each cell line and presented as a table. E, Apoptosis quantification of all cell lines used in B (except H1792) after 72 hours of exposure to either 100 nmol/L docetaxel or 100 nmol/L paclitaxel. Cells were stained with FITC-conjugated annexin V to detect apoptotic cells. n = 3 biological repeats per cell line with the mean of three biological repeats shown as a dot. Error bars represent mean ± SEM of all cell lines within each condition. F, Viability of advanced cancer cell lines expressing (left) KRASG13C and (right) KRASG12C, KRASG12D, and KRASG13D grouped together, exposed to 1 μmol/L vincristine or either 100 or 1,000 nmol/L navitoclax or both compounds in combination. Viability was measured by CellTiter-Glo (3D) 72 hours later. Data are expressed as a percentage of DMSO control. n = 3 per cell line with the mean of 2 or 3 biological repeats shown as a dot. Error bars represent mean ± SEM of all cell lines within each condition. G, Viability of advanced cancer cell lines expressing (left) KRASG13C and (right) KRASG12C, KRASG12D, and KRASG13D grouped together exposed to 1 μmol/L epirubicin or either 100 or 1,000 nmol/L navitoclax or both compounds in combination. Viability was measured by CellTiter-Glo (3D) 72 hours later. Data are expressed as a percentage of DMSO control. n = 3 per cell line with the mean of 2 or 3 biological repeats shown as a dot. Error bars represent mean ± SEM of all cell lines within each condition. Statistical significance between comparisons was calculated using an unpaired Student t test (B), log-rank (Mantel–Cox; C), a two-way ANOVA (E), and a one-way ANOVA (F and G). COMB, combination. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns > 0.05.